Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

BACKGROUND: Bone metastases are a major burden in men with advanced prostate cancer. We compared denosumab, a human monoclonal antibody against RANKL, with zoledronic acid for prevention of skeletal-related events in men with bone metastases from castration-resistant prostate cancer. METHODS: In thi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Fizazi, Karim, Carducci, Michael, Smith, Matthew, Damião, Ronaldo, Brown, Janet, Karsh, Lawrence, Milecki, Piotr, Shore, Neal, Rader, Michael, Wang, Huei, Jiang, Qi, Tadros, Sylvia, Dansey, Roger, Goessl, Carsten
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2011
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3090685/
https://ncbi.nlm.nih.gov/pubmed/21353695
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(10)62344-6
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller